HIF1A and neoplasm: The immunohistochemical profiling was investigating on tumor sample at diagnosis the 2 targets: activated phospho-mTor and HIF-1α, but also phospho-Akt, which is upstream to mTorc1 and stimulating its expression, and HIF-2α, which was underlined as a biomarker of treatment resistance in our in vitro preclinical work [25].